NCT02223247

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Sagimet Biosciences Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This first in human phase 1 study of TVB-2640 is being conducted in patients with advanced stage solid malignant tumors. This research is being done to find out how safe and useful TVB-2640 is for patients who have received previous cancer therapy, and for whom no therapy exists that would be curative or might provide significant benefit. TVB-2640 belongs to a class of drugs called fatty acid synthase inhibitors (FASN inhibitors). This means that they interfere with the body's (and the tumor's) ability to use a substance called fatty acid synthase (FASN). Research has shown that some tumors appear to need FASN to keep growing.

Conditions

• Solid Malignant Tumor

Interventions

Type	Name	Description
DRUG	TVB-2640

Timeline

• Start date: 2013-11-01
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2014-08-22
• Last updated: 2017-08-14

Locations

11 sites across 2 countries: United States, United Kingdom

Regulatory

• FDA-regulated drug study